User fees: 3rd-party and EU CAB (conformity assessment body) reviewed-devices need not pay
This article was originally published in Clinica
The US FDA offers both good and bad news in a new guidance document discussing the less obvious examples of when it will assess a user fee and when it will not. On the positive side, user fees will not be charged if the device is submitted by a state or government official, is solely intended for children, or when the 510(k) has already been reviewed by a US third party or an EU conformity assessment body, it said.
You may also be interested in...
The US agency says in the latest update to its medical device shortages guidance doc that it’ll send enforcement missives to companies that don’t notify the agency of a “permanent discontinuance or an interruption in manufacturing” of products deemed critical during the COVID-19 pandemic.
As the first emergency use authorization is granted, Pfizer and Moderna stand accused of neglecting poorer nations as wealthy countries snap up early access to COVID-19 vaccines.
Tensions between industry and the European Commission on the issue of health claims for botanical food supplements were aired on the second day of the BAH's High Level Conference on the Future of Medicines, with the EC saying the EU Green Deal is now higher up on its list of priorities for the foreseeable future.